期刊文献+

聚乳酸-羟基乙酸纳米粒的制备 被引量:2

Preparation of poly lactic acid-glycolic acid nanoparticles
下载PDF
导出
摘要 背景:聚乳酸-羟基乙酸是一种生物相容性良好的可降解材料,确定其最佳制备工艺条件,有利于聚乳酸-羟基乙酸后续药物载体研究与工业化生产条件的确立。目的:以聚乳酸-羟基乙酸为包裹材料,探索纳米粒的制备条件对粒径、表面形态等的影响,确定最佳制备工艺条件。方法:采用乳化-溶剂挥发法制备聚乳酸-羟基乙酸纳米粒,以粒径为观察指标,探讨乳化剂种类、乳化剂含量、油相种类、超声时间、挥发时间、油相与水相体积比(W∶O)以及聚合物质量浓度等制备条件对纳米粒粒径的影响,确定制备聚乳酸-羟基乙酸纳米粒的最佳工艺条件。结果与结论:优化后的制备工艺条件是在室温下,以一定的搅拌速度和滴加速度,选择常用无毒的乳化剂,浓度在0.3%~1.0%,丙酮为有机相,超声时间8~15min、挥发时间6~10h、水油相比(W∶O)〉25∶1,聚合物质量浓度〈60g/L。提示该制备工艺简单、稳定,优化制备条件,可制备出表面形态规整、粒径适宜的聚乳酸-羟基乙酸纳米粒。 BACKGROUND: Poly lactic acid-glycolic acid (PLGA) is a type of biodegradable material with good biocompatibility. Optimum preparation conditions of PLGA are conductive to the follow-up studies of drug delivery and their establishment of industrial production conditions. OBJECTIVE: To explore the effects of preparation conditions of nanoparticles based on the wrapping material of PLGA on their particle size and surface morphology, and determine the optimum preparation and process. METHODS: PLGA nanoparticles were prepared using emulsion-solvent evaporation technique. The particle size of nanoparticles was measured. The effects of emulsifier type, emulsifier concentration, oil phase type, sonic time, volatile time, the volume ratio of water to oil, and polymer concentration on the particle size were analyzed to establish the optimum preparation conditions of PLGA. RESULTS AND CONCLUSION: The optimization parameters at the room temperature, with a certain stirring speed and drop acceleration, selection of the commonly used nontoxic emulsifier, the concentration was from 0.3% to 1%, acetone as organic phase, extraction time was from 8 to 15 minutes, volatile time was from 6 to 10 hours, ratio of water and oil 25:1, and the polymer concentration 60 g/L. The preparation process is simple, stable and optimized. The PLGA nanoparticles can be prepared with structured morphology surface and proper particle size.
出处 《中国组织工程研究与临床康复》 CAS CSCD 2012年第3期396-400,共5页 Journal of Clinical Rehabilitative Tissue Engineering Research
基金 广东省自然科学基金面上项目资助(9151052005000006)~~
  • 相关文献

参考文献21

  • 1Schnieders J,Gbureck U,Thull R,et al.Controlled release of gentamicin from calcium phosphate-poly(lactic acid-co-glycolic acid) composite bone cement.Biomaterials.2006;27(23):4239-4249.
  • 2凌友,黄岳山,梁常艳.乳酸-羟基乙酸共聚物纳米粒的研究进展[J].中国组织工程研究与临床康复,2008,12(10):1899-1902. 被引量:15
  • 3Kakizawa Y,Nishio R,Hirano T,et al.Controlled release of protein drugs from newly developed amphiphilic polymer-based microparticles composed of nanoparticles.J Control Release.2010;142(1):8-13.
  • 4Juillerat-Jeanneret L.The targeted delivery of cancer drugs across the blood-brain barrier:chemical modifications of drugs or drug-nanoparticles? Drug Discov Today.2008;13(23-24):1099-1106.
  • 5Olivier JC.Drug transport to brain with targeted nanoparticles.NeuroRx.2005;2(1):108-119.
  • 6Jeong YI,Na HS,Seo DH,et al.Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.Int J Pharm.2008;352(1 -2):317-323.
  • 7Tivadar Feczkó,Judit Tóth,János Gyenis.Colloids and Surfaces A:Physicochemical and Engineering Aspects.2007;7:1-8.
  • 8Perron JK,Naguib HE,Daka J,et al.A study on the effect of degradation media on the physical and mechanical properties of porous PLGA 85/15 scaffolds.J Biomed Mater Res B Appl Biomater.2009;91(2):876-886.
  • 9Habraken WJ,Wolke JG,Mikos AG,et al.PLGA microsphere/calcium phosphate cement composites for tissue engineering:in vitro release and degradation characteristics.J Biomater Sci Polym Ed.2008;19(9):1171-1188.
  • 10Jaklenec A,Hinckfuss A,Bilgen B,et al.Sequential release of bioactive IGF-I and TGF-beta 1 from PLGA microsphere-based scaffolds.Biomaterials.2008;29(10):1518-1525.

二级参考文献51

共引文献19

同被引文献46

  • 1寇龙发,高利芳,姚情,李东坡,孙进.乳化溶剂挥发法制备紫杉醇PLGA纳米粒及其体外评价[J].中国药剂学杂志(网络版),2014,12(2):33-42. 被引量:9
  • 2YE X, LI J, LU M X, et al. Identification and molecular typing of Streptococcus agalactiae isolated from pond-cultured tilapia in China [J]. FishSei, 2011, 77(4): 623-632.
  • 3EVANS J J, KLESIUS P, SHOEMAKER C A, et al. Streptococcus agalactiae vaccination and infection stress in Nile tilapia, Oreochro- mis niloticus[J]. J Appl Aquac, 2005, 16(3) : 105 -115.
  • 4PRETTO L G, MULLER E E, KLESIUS P, et al. Efficacy of an experimentally inactivated Streptococcus agalactiae vaccine in Nile ti- lapia ( Oreochromis niloticus ) reared in Brazil [ J ]. Aquae Res, 2010, 41(10): 1539 -1544.
  • 5MAKADIA H K, SIEGEL S J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier [ J ]. Polymers, 2011, 3(3): 1377-1397.
  • 6JEFFERY H, DAVIS S S, OHAGAN D T. The preparation and characterization of poly ( lactide-co-glycolide ) micropariicles. 2. The entrapment of a model protein using a (water-in-oil) -in-water emulsion solvent evaporation technique [ J ]. Pharm Res, 1993, 10(3) : 362-368.
  • 7YANG Y Y, CHUNGTS, NGEE P N. Morphology, drug distri- bution, and in vitro release profiles of biodegradable polymeric mi- erospheres containing protein fabricated by double-emulsion solvent extraction/evaporation method[ Jl. Biomaterials, 2001, 22 (3) : 231 -241.
  • 8JAIN R A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) ( PLGA ) devices [ J ]. Biomaterials, 2000, 21(23): 2475-2490.
  • 9ZIMMERMANN W H, SCHNEIDERBANGER K, SCHUBERT P, et at. Tissue engineering of a differentiated cardiac muscle con- struct[J]. Circ Res, 2002, 90(2): 223-230.
  • 10TIAN J, SUN X Q, CHEN X G, et al. The formulation and im- munization of oral poly (DL-lactide-co-glycolide) microcapsules containing a plasmid vaccine against lymphocystis disease virus in Japanese flounder ( Paralichthys olivaceus ) [ J ]. Int Immunop- harmacol, 2008, 8 (6) : 900 - 908.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部